EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.
about
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expressionQuantifying factors for the success of stratified medicine.Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture modelMolecular biomarkers in clinical development: what could we learn from the clinical trial registry?
P2860
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
EGF-receptor targeting with mo ...... or a pharmacogenomic approach.
@en
EGF-receptor targeting with mo ...... or a pharmacogenomic approach.
@nl
type
label
EGF-receptor targeting with mo ...... or a pharmacogenomic approach.
@en
EGF-receptor targeting with mo ...... or a pharmacogenomic approach.
@nl
prefLabel
EGF-receptor targeting with mo ...... or a pharmacogenomic approach.
@en
EGF-receptor targeting with mo ...... or a pharmacogenomic approach.
@nl
P2093
P2860
P356
P1433
P1476
EGF-receptor targeting with mo ...... or a pharmacogenomic approach.
@en
P2093
Alfredo Falcone
Enrico Vasile
Fotios Loupakis
Francesco Graziano
Gianluca Masi
P2860
P356
10.2217/14622416.9.1.55
P577
2008-01-01T00:00:00Z